Each 5 mL contains Dextromethorphan Hydrobromide 10 mg, Chlorpheniramine Maleate 2 mg, and Phenylephrine Hydrochloride 5 mg.

Ventryl D Syrup is a triple-action formulation containing Dextromethorphan Hydrobromide, Chlorpheniramine Maleate, and Phenylephrine Hydrochloride for effective relief from dry cough and upper respiratory tract symptoms. It suppresses the cough reflex, relieves allergy-related symptoms such as sneezing and runny nose, and reduces nasal congestion to improve breathing comfort. The combination provides comprehensive symptomatic relief associated with the common cold and upper respiratory tract infections.

Ventryl D Syrup is indicated for the symptomatic relief of dry cough and upper respiratory tract symptoms, including nasal congestion, sneezing, runny nose, and throat irritation associated with the common cold and allergic conditions.

Dextromethorphan Hydrobromide is a non-narcotic antitussive that acts on the medullary cough center, increasing the cough threshold and effectively suppressing dry, irritating cough without producing significant analgesic or addictive effects. Chlorpheniramine Maleate is a first-generation H1-antihistamine that competitively blocks histamine receptors, reducing sneezing, rhinorrhea, and other allergic symptoms. It also possesses mild antimuscarinic, moderate antiserotonin, and local anesthetic properties. Phenylephrine Hydrochloride is a sympathomimetic alpha-adrenergic agonist that constricts nasal blood vessels, reducing mucosal swelling and relieving nasal congestion.

The recommended dosage for children aged 6–11 years is 5 mL orally every 4 hours, not exceeding 6 doses in 24 hours. For adults and children aged 12 years and above, the recommended dosage is 10 mL orally every 4 hours, not exceeding 6 doses daily, or as directed by the physician.

Ventryl D Syrup is contraindicated in patients with known hypersensitivity to Dextromethorphan Hydrobromide, Chlorpheniramine Maleate, Phenylephrine Hydrochloride, or any component of the formulation. It is also contraindicated in patients with a history of quinidine-, quinine-, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions.